Literature DB >> 34246179

Pulmonary sclerosing pneumocytoma masquerading adenocarcinoma with co-existing BRAF V600E and PTEN mutation.

Klein Dantis1, Ashish Kumar Gupta2, Nitin Kumar Kashyap3, Yashwant Kashyap4, T Ganga Ranganath5, Saroj Kumar Pati6, Mayank Kumar7, Shiva Thakur8, Mudalsha Ravina9.   

Abstract

We report a case of a massive primary sclerosing pneumocytoma (PSP) involving the right lower lobe adhering esophagus with small synchronous PSP on the superior segment of the left lower lobe with concurrent mutation for B-RAF proto-oncogene, serine/threonine kinase (BRAF V600E), and phosphatase and tensin homolog (PTEN) gene in a young female. She underwent right lower lobectomy and mediastinal lymph node dissection under single lung ventilation with tumor-free margins on diagnosis-based findings of preoperative computed tomography-guided biopsy and positron emission tomography. Histopathology was suggestive of PSP-papillary variant with concurrent mutation of BRAF V600E and PTEN genes. Post-operative follow-up at four weeks was uneventful. She has to undergo wedge resection for the contralateral disease after six weeks following recovery from the first surgery.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; BRAF V600E; Esophagus; Mutation; PTEN; Sclerosing pneumocytoma; Synchronous

Mesh:

Substances:

Year:  2021        PMID: 34246179     DOI: 10.1016/j.ctarc.2021.100429

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN: 2468-2942


  2 in total

Review 1.  Pulmonary sclerosing pneumocytoma: clinical features and prognosis.

Authors:  Quan Zheng; Jian Zhou; Guangchen Li; Shulei Man; Zhangyu Lin; Tengyong Wang; Boran Chen; Feng Lin
Journal:  World J Surg Oncol       Date:  2022-04-30       Impact factor: 3.253

Review 2.  The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.

Authors:  Longyao Zhang; Linpeng Zheng; Qiao Yang; Jianguo Sun
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.